Patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2 research hub

ETOP 29-25 START-lung: A multicentre phase II trial of tarlatamab in patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2.

This study is testing a new medicine called tarlatamab for people with advanced small cell lung cancer that has already been treated. We want to see how well it helps people live longer and if it has any side effects, particularly for those who are a bit frailer.